A detailed history of State Street Corp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 3,468,514 shares of SMMT stock, worth $62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,468,514
Previous 4,123,137 15.88%
Holding current value
$62 Million
Previous $32.2 Million 136.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.89 - $31.93 $4.51 Million - $20.9 Million
-654,623 Reduced 15.88%
3,468,514 $76 Million
Q2 2024

Aug 14, 2024

SELL
$2.39 - $10.92 $9.54 Million - $43.6 Million
-3,991,093 Reduced 49.19%
4,123,137 $32.2 Million
Q1 2024

May 15, 2024

BUY
$2.55 - $5.07 $14.4 Million - $28.7 Million
5,658,062 Added 230.36%
8,114,230 $33.6 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.83 $316,630 - $536,565
189,599 Added 8.37%
2,456,168 $6.41 Million
Q3 2023

Nov 14, 2023

BUY
$1.54 - $2.42 $19,394 - $30,477
12,594 Added 0.56%
2,266,569 $4.24 Million
Q2 2023

Aug 14, 2023

BUY
$1.32 - $2.81 $2.81 Million - $5.99 Million
2,131,675 Added 1742.99%
2,253,975 $5.66 Million
Q1 2023

May 15, 2023

BUY
$1.38 - $5.41 $47,471 - $186,104
34,400 Added 39.14%
122,300 $214,000
Q4 2022

Feb 14, 2023

BUY
$0.68 - $5.31 $59,772 - $466,748
87,900 New
87,900 $373,000
Q2 2022

Aug 15, 2022

SELL
$0.92 - $2.38 $288,328 - $745,894
-313,401 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.0 - $3.45 $47,426 - $81,809
-23,713 Reduced 7.03%
313,401 $768,000
Q4 2021

Feb 14, 2022

BUY
$2.45 - $5.64 $2,244 - $5,166
916 Added 0.27%
337,114 $907,000
Q3 2021

Nov 15, 2021

BUY
$4.83 - $8.27 $383,975 - $657,448
79,498 Added 30.97%
336,198 $1.68 Million
Q2 2021

Aug 16, 2021

BUY
$5.15 - $8.46 $1.32 Million - $2.17 Million
256,700 New
256,700 $1.92 Million

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.6B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.